Novartis AG (LSE:0HKE)
£ 3657.04 0 (0%) Market Cap: 60.95 Bil Enterprise Value: 74.78 Bil PE Ratio: 14.34 PB Ratio: 5.34 GF Score: 77/100

Novartis AG Materiality Assessment Webinar: Dialogue Matters Transcript

Feb 08, 2021 / 02:00PM GMT
Jeffrey L. Sturchio
Rabin Martin - Chairman

I'm the moderator for today's Novartis Materiality Assessment 2021 kickoff webinar, and it's a pleasure to welcome you all to today's discussion. The next slide will give us the agenda for our discussion. And you can see that we'll be taking a look at why materiality assessment is important, what has Novartis achieved, where are they heading, and also there will be an opportunity, as usual, to hear from all of you with your questions and comments. The next slide is just some logistics for us. The duration of the meeting will be an hour. (Operator Instructions)

Now let me turn to our speakers and introduce our panel. We have a distinguished group of speakers from Novartis. On the next slide, we'll show some photos of them. We'll be hearing first from Patrice Matchaba, who's the Head of U.S. Corporate Responsibility and President of the Novartis U.S. Foundation; Dr. Lutz Hegemann, who's the Group Head of Corporate Affairs and Global Health; Samir Shah, the Head of Investor Relations; and Carrie Scott, the Head of the ESG Management Office.

So

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot